RARahaf Altahan

Rahaf Altahan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rahaf Altahan has a total of 27 co-authors. Here are the top co-authors by number of shared publications:

  • Abdul Ali Peer Zada

    Department of Medical Genetics and Molecular Pathology, Pathology and Clinical Laboratory Medicine Administration King Fahad Medical City Riyadh Saudi Arabia

    2 shared publications
  • Ahmad Al-Zghoul

    Flow cytometry Lab, Department of Pathology and Laboratory Medicine, King Abdulaziz Medical City, Riyadh, Saudi Arabia

    1 shared publication
  • Alex Bourguignon

    Department of Pathology and Molecular Medicine McMaster University Hamilton Ontario Canada

    1 shared publication
  • Areej Al Mugairi

    Hematopathology Division, Department of Pathology and Laboratory Medicine, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh 11426, Saudi Arabia

    1 shared publication
  • Areej AlMugairi

    Division of Hematopathology, Department of Pathology and Laboratory Medicine, King Abdulaziz Medical City, Riyadh, Saudi Arabia

    1 shared publication
  • Aziza Alswayyed

    Pathology and Clinical Laboratory Medicine Administration King Fahad Medical City Riyadh Saudi Arabia

    1 shared publication

Latest Publications

  • Open Access

    Acquired platelet disorders

    by Rahaf Mahmoud Altahan

    Platelets are essential to primary hemostasis, and defects in their number or function can lead to clinically significant bleeding or thrombosis. Acquired platelet disorders are far more common than the inherited forms and arise in a wide range of settings, including drug exposure, autoimmune, systemic, and critical illnesses. This review examines current understanding of the mechanisms driving acquired platelet dysfunction and outlines the diagnostic and therapeutic approaches that are shaping contemporary standards of care. Drug-related and immune-mediated platelet defects remain the most recognized causes in clinical practice. Nevertheless, increasing evidence points to inflammation, particularly the profound dysregulation seen in sepsis, as a major contributor to abnormal platelet behavior. Although sepsis-associated platelet defects are frequent in practice and correlate with organ injury and adverse outcomes, they are rarely acknowledged in traditional frameworks of “acquired platelet disorders,” which tend to focus on classic hematologic and pharmacologic causes. This review summarizes current evidence on acquired platelet disorders and emphasizes the clinical and pathophysiologic relevance of sepsis-induced platelet dysfunction.


  • Open Access

    Evaluation of a diagnostic platelet aggregation test strategy for platelet rich plasma samples with low platelet counts

    by Rahaf Mahmoud Altahan, Natalie Mathews, Alex Bourguignon, Subia Tasneem, Donald M. Arnold, Wendy Lim, Catherine P. M. Hayward

    Introduction: Light transmission aggregometry (LTA) is important for diagnosing platelet function disorders (PFD) and von Willebrand disease (VWD) affecting ristocetin‐induced platelet aggregation (RIPA). Nonetheless, data is lacking on the utility of LTA for investigating thrombocytopenic patients and platelet rich plasma samples with low platelet counts (L‐PRP). Previously, we developed a strategy for diagnostic LTA assessment of L‐PRP that included: (1) acceptance of referrals/samples, regardless of thrombocytopenia severity, (2) tailored agonist selection, based on which are informative for L‐PRP with mildly or severely low platelet counts, and (3) interpretation of maximal aggregation (MA) using regression‐derived 95% confidence intervals, determined for diluted control L‐PRP (C‐L‐PRP).Methods: To further evaluate the L‐PRP LTA strategy, we evaluated findings for a subsequent patient cohort.Results: Between 2008 and 2021, the L‐PRP strategy was applied to 211 samples (11.7% of all LTA samples) from 192 unique patients, whose platelet counts (median [range] × 109/L) for blood and L‐PRP were: 105 [13–282; 89% with thrombocytopenia] and 164 [17–249], respectively. Patient‐L‐PRP had more abnormal MA findings than simultaneously tested C‐L‐PRP (p‐values n = 181), L‐PRP LTA uncovered significant aggregation abnormalities in 45 (24.9%), including 18/30 (60%) with 9 platelets/L L‐PRP, and ruled out PFD, and VWD affecting RIPA, in others. The L‐PRP LTA strategy helped diagnose VWD affecting RIPA, Bernard Soulier syndrome, familial platelet disorder with myeloid malignancy, suspected ITGA2B/ITGB3‐related thrombocytopenia, and acquired PFD.Conclusion: Diagnostic LTA with L‐PRP, using a strategy that considers thrombocytopenia severity, is feasible and informative.


  • Open Access

    An unusual non‐hematopoietic bone marrow finding

    by Rahaf Altahan, Mohammed Lafi Alanazi, Mohammed Abdulaziz Alharbi, Salman Almalki, Aziza Alswayyed, Laila Alsuhaibani

    Key Clinical Message: We present an interesting case that showed a non‐hematopoietic structure embedded in the bone marrow biopsy. Given the clinical and morphological difficulties, it was challenging to identify this artifact's nature. Publishing this case would familiarize pathologists with this artifact and save additional testing and delays in reporting.


  • Open Access

    Favorable outcome of PML‐RARα short isoform and FLT3‐ITD mutation in a patient with several adverse prognostic markers: A case report

    by Mohammed A. Bafail, Rahaf AlTahan, Manar A. Samman, Suha A. Tashkandi, Ibraheem H. Motabi, Abdul Ali Peer‐Zada

    Key Clinical Message: Complete molecular remission in a “variant APL” patient with short isoform of PML‐RARα and FLT3‐ITD mutation was achieved in response to ATRA and ATO plus IDA instead of standard treatment protocol. The use of FLT3 inhibitor in APL induction management is implicated to prevent differentiation syndrome and coagulopathy experienced in in patients with FLT3‐ITD. FLT3‐ITD mutations are the most common activating mutations in FLT3 gene, occurring in about 12 to 38% of acute promyelocytic leukemia cases, and are mainly associated with high white blood cell counts and poor clinical outcomes. Here, we present a case of APL variant with adverse prognostic features who showed short isoform [bcr3] of PML‐RARα and FLT3‐ITD mutation at diagnosis. The patient received all‐trans retinoic acid (ATRA) and arsenic trioxide (ATO) plus idarubicin (IDA) instead of standard treatment protocol, and achieved a complete morphological, cytogenetic and molecular response. However, the patient experienced differentiation syndrome, and coagulopathy that was subsequently resolved by continuous oxygen therapy, dexamethasone, and enoxaparin. The use of FLT3 inhibitor in APL induction management is implicated to prevent differentiation syndrome and coagulopathy in patients with FLT3‐ITD mutation.


  • Open Access

    Outcome of PML-RARα Short Isoform and FLT3-ITD in a Patient with Several Adverse Prognostic Markers: a Case Report

    by Mohammed Bafail, Rahaf Altahan, Manar Samman, Suha Tashkandi, Ibraheem Motabi, Abdul Ali Peer Zada

    Title: Outcome of PML-RARα Short Isoform and FLT3-ITD in a Patient with Several Adverse Prognostic Markers: a Case ReportMohammed A Bafail1, Rahaf AlTahan1Manar A Samman1, Suha A Tashkandi1, Ibraheem H Motabi2 , Abdul Ali Peer-Zada1*

  • Open Access

    Relapsed Angioimmunoblastic T Cell Lymphoma with Fulminant Leukemic Involvement

    by Rahaf Altahan, Areej AlMugairi, Muhamed Hitham Almahayni, Moussab Damlaj, Ahmad Al-Zghoul

    Relapsed Angioimmunoblastic T Cell Lymphoma with Fulminant Leukemic Involvement - Article abstract #936448

  • Open Access

    The unusual abundance of a rare finding!

    by Rahaf Altahan, Areej Al Mugairi

    We present images (Figure 1A‐D) of a preterm girl who had severe anemia due to HDFN caused by maternal anti‐C and anti‐D alloantibodies. These images show erythrophagocytosis, which is a very interesting and rarely encountered feature. We believe that physicians taking care of such patients should be more aware of this characteristic yet under‐detected finding.


  • Open Access

    Non‐acute promyelocytic leukemia variant, acute myeloid leukemia with translocation (11;17)

    by Rahaf Altahan, Shatha Altahan, Salem Khalil

    Key Clinical Message: t(11;17) is a rare but recognized finding usually found in Acute Promyelocytic Leukemia with variant RARA translocation (APLv). We present a case of Acute Myeloid Leukemia with t(11;17) that has different break points than those occurring in APLv. The diagnosis of acute myeloid leukemia, not otherwise specified, acute monoblastic leukemia was reached after a thorough investigation. Reaching the correct diagnosis and distinguishing these two entities are essential as they have different management, prognosis, and overall survival.